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Human BLCAP transcript: new editing events in normal and
cancerous tissues
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Concezio Di Rocco4, Mary A. O’Connell2 and Angela Gallo1
1 Ospedale Pediatrico Bambino Gesu`, Piazza S. Onofrio, 4, 00165 Rome, Italy
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3 Institute of Cancer Biology, Danish Cancer Society, Danish Centre for Translational Breast Cancer Research, Copenhagen, Denmark
4 Pediatric Neurosurgery Policlinico Gemelli, Largo Agostino Gemelli, 8, 00168 Rome, Italy
Bladder cancer-associated protein (BLCAP) is a highly conserved protein among species, and it is considered a novel
candidate tumor suppressor gene originally identified from human bladder carcinoma. However, little is known about the
regulation or the function of this protein. Here, we show that the human BLCAP transcript undergoes multiple A-to-I editing
events. Some of the new editing events alter the highly conserved amino terminus of the protein creating alternative protein
isoforms by changing the genetically coded amino acids. We found that both ADAR1 and ADAR2-editing enzymes cooperate to
edit this transcript and that different tissues displayed distinctive ratios of edited and unedited BLCAP transcripts. Moreover,
we observed a general decrease in BLCAP-editing level in astrocytomas, bladder cancer and colorectal cancer when compared
with the related normal tissues. The newly identified editing events, found to be downregulated in cancers, could be useful
for future studies as a diagnostic tool to distinguish malignancies or epigenetic changes in different tumors.
In eukaryotes, mRNA transcripts are extensively processed by
post-transcriptional events such as alternative splicing and
RNA editing to generate different mRNAs from the same gene.
In mammals, the most common type of editing involves the
conversion of adenosines into inosines.1,2 A-to-I RNA editing
has the potential to change the RNA sequence, in fact, inosine
is read as guanosine by both the translation machinery3 and
the splicing machinery.4 Furthermore, the inosine does not pair
with uracil but instead with cytosine, changing the (A–U) base
pair into an (I:U) mismatch.5 Therefore, A-to-I editing has also
the potential to change the secondary structure of RNA mole-
cules. This type of editing is catalyzed by a family of enzymes
called adenosine deaminases acting on RNA (ADARs). ADARs
have a conserved domain arrangement that include 2 or 3
dsRNA-binding domains (RBDs) at the amino terminus and a
highly conserved deaminase domain at the carboxy terminus.1,6
Three ADARs have been identiﬁed. ADAR1 and ADAR2 are
widely expressed and active enzymes however, ADAR3 is pres-
ent exclusively in the brain and is inactive in vitro assays.7,8
The total amount of inosines present in mammalian tissues
was found to occur at a higher frequency than previously esti-
mated.9 Furthermore, it has been shown that the majority of
the A-to-I substitutions occur not within the coding region of
mRNAs but in noncoding RNA sequences particularly within
the untranslated regions (UTRs).10–12 Transcripts edited within
their coding sequence are mainly expressed in the central nerv-
ous system (CNS) and, as a consequence, alterations in RNA
editing are often implicated in pathologies that affect the CNS
such as epilepsy,13 depression,14 ALS15 and brain tumors.16–20
RNA-editing levels change during neuronal-cell differen-
tiation and vary within different regions of the brain.18,21–23
However, little is known about how and if ADARs are differ-
ently modulated in vivo in tissues other than the brain. This
could be important as these enzymes are widely expressed
and their activity is essential in tissues of non-neurological
origin.24 Therefore, identiﬁcation of additional ADAR sub-
strates in these tissues would assist in understanding the reg-
ulation of the ADAR enzymes. Recently, considerable effort
has been spent in this area of research.10,25–27 We focused
our attention on a transcript that is ubiquitously expressed
that encodes bladder cancer-associated protein (BLCAP) also
known as BC10 protein (bladder cancer-10 kDa protein) that
is an 87 amino acid protein with 2 hypothetical transmem-
brane regions (TM).28,29 Importantly, it has been shown that
the mRNA of BLCAP is downregulated in bladder invasive
carcinoma28 and in renal cell carcinoma30 and in primary
cervical carcinoma,31 underlining the potential onco-
Key words: RNA editing, ADARs, BLCAP, cancer, dsRNA structure
Additional Supporting Information may be found in the online
version of this article.The ﬁrst two authors contributed equally to
this work.
Grant sponsor: MRC; Grant number: U.1275.01.005.00001.01;
Grant sponsor: AIRC (Associazione Italiana per la Ricerca sul
Cancro)
DOI: 10.1002/ijc.25022
History: Received 20 May 2009; Accepted 27 Oct 2009; Online 11
Nov 2009
Correspondence to: Angela Gallo, Ospedale Pediatrico Bambino
Gesu`, Piazza S. Onofrio, 4, 00165 Rome, Italy, Tel.:
þ39-06-68592658, Fax: þ39-06-68592904, E-mail: gallo@opbg.net
E
ar
ly
D
et
ec
ti
on
an
d
D
ia
gn
os
is
Int. J. Cancer: 127, 127–137 (2010) VC 2009 UICC
International Journal of Cancer
IJC
suppressive role of this protein. Nevertheless, the biological
role of BLCAP has not yet been elucidated.
Here, we identify novel editing sites in the human BLCAP
transcript in both coding and noncoding sequences. We
found that the new editing events were present in the differ-
ent human tissues studied and that the percentage of editing
varies strongly depending on the tissues analyzed. We found
that both ADAR1 and ADAR2 play a cooperative role in
editing this substrate. Our work opens up new possibilities in
studying the regulation of ADARs and their activity in differ-
ent cell types and tissues by monitoring the editing in the
BLCAP transcript. Moreover, we report that editing of the
BLCAP transcript is downregulated in cancerous tissues that
could be of importance for future-improved diagnosis and
prognosis in a variety of different cancer types.
Material and Methods
Tissues and cell lines
Tissue and cell-line samples used in this study were identiﬁed
by progressive identiﬁcation numbers, ID 1–21:
(ID1) human heart from Clonthech, BD Biosciences;
(ID2) human bladder from Clonthech, BD Biosciences; (ID3)
normal blood lymphocytes, patient 2630; (ID4) normal epi-
thelial tissue from colonic normal mucosa, patient 2630;
(ID5) skin ﬁbroblast from patient 2630; (ID6) white matter,
patient n.22; (ID7) human bladder carcinoma grade II, (ID8)
human bladder carcinoma grade III; (ID9) human bladder
carcinoma grade III 727-1; (ID10) tumorigenic human blad-
der cell line (TCC) HU 609 (kind gift from Dr. Toben Ørn-
toft, Denmark); (ID11) human bladder cell line (TCC) HCV
29 (kind gift from Dr. Toben Ørntoft, Denmark); (ID12)
human bladder epithelial invasive carcinoma cell line (TCC)
T24 (ATCC); (ID13) colorectal cancerous epithelial tissue
from a polyp developed by patient 2630; (ID14) colorectal
cancerous epithelial tissue from patient 425; (ID15) epithelial
colorectal cancer cell line from patient 425 (MYH deﬁcient),
VACO425; (ID16) epithelial colorectal cancer cell line
CACO2; (ID17) epithelial colorectal cancer cell line HRT18;
(ID18) pediatric astrocytoma grade IV patient n.22; (ID19)
astrocytoma cell line U118 MG (ATCC); (ID20) astrocytoma
cell line A172 (ATCC); (ID21) HeLa cell line (ATCC). All
the samples identiﬁed by ID numbers were tested for RNA-
editing levels on a BLCAP transcript after RT-PCR, and indi-
vidual cDNA clones were sequenced for each sample. Fresh
tumor and control tissues were dissected and placed on dry
ice until required. Tumor cell lines were maintained in Dul-
becco’s modiﬁed Eagle’s medium (DMEM) supplemented
with 10% fetal calf serum (FCS) and 1% penicillin–
streptomycin.
Extraction of RNA
Total RNA was isolated with TRIzol Reagent (GIBCO) from
tumors, control tissues and cultured cell lines according to
the manufacturer’s instructions.
RT-PCR from the different tissues and cell lines
One microgram of puriﬁed total RNAs pretreated with
DNase I was incubated at 70C in the presence of 1 lM of
the appropriate speciﬁc reverse primer. The hBLCAP-30RT
primer 50-CCGTCTTCTGCTTCCTTGGAAAGCTAACAG-30
was used to reverse transcribe part of the 30UTR, the coding
sequence and the 50UTR of BLCAP. The 30RT primer 50-
GAAGAGAAAAGTCAACACAACAGACAAACA-30 was
used to reverse transcribe the pre-mRNA that includes the
intron. After a 30-min incubation the samples were placed
on ice for 5 min. Reactions were then performed in the pres-
ence or absence of M-MLV reverse transcriptase, RNase H
Minus (Promega), following the suppliers instructions and
incubated for 2 h at 42C. The cDNA obtained was ampliﬁed
by PCR with the expand high ﬁdelity PCR System (Roche).
hBLCAP-50F 50-GATCCCTGCTGCCTTGGTGATCCCGGG
CTG-30 and hBLCAP-30RT were used to amplify a fragment
of 479 bp encompassing the 50UTR, ORF and 39 bp of the
30UTR. hBLCAP-intron50 50-CTTAAAATATTTCGAGGCTG
TAGCTGCCTC-30 and hBLCAP-intron 3RT were used to
amplify a fragment of 580 bp within the intron that was pre-
dicted by bioinformatics to base pair with exon 2 and thus
form a double-stranded substrate for the ADAR enzymes.
Thirty cycles of the following PCR program were used: dena-
turing 30 s at 94C, annealing 30 s at 58C and extension for
1 min at 68C. Speciﬁc products were gel puriﬁed (Qiaquick,
Qiagen) and directly sequenced or cloned into pGEM T-easy
vector (Promega) and transformed into Escherichia coli and
sequenced with T7 and Sp6.
Analysis of RNA editing
Sequences were analyzed with Seqman software (Lasergene),
and direct sequencing was performed on cDNA pools. Edit-
ing was calculated as previously described32 or the PCR prod-
ucts were subcloned into the T-easy vector (Promega), and
30–50 individual cDNA clones were sequenced for each
sample. A–G changes in the individual clones were analyzed.
For each sample, 2–3 independent RT-PCR reactions were
performed.
Astrocytoma and HEK 293T cell lines
cDNA, encoding the shorter and more active human isoform
ADAR2a and the human ADAR1 long isoform (ADAR1
150kDa), were subcloned into pEGFP C3 vector (V-EGFP)
(Clontech) with in-frame enhanced green ﬂuorescent protein
(EGFP) at the amino terminus. The HEK 293T cell line was
cultured in DMEM.
HEK 293T cell line was chosen for the assessment of
EGFP-ADAR2 and EGFP-ADAR1-editing activity on the
BLCAP transcript, as the endogenous editing activity in this
cell line is low or undetectable.18,20,33 The HEK 293T cell line
was cultured in DMEM and 7  105 HEK 293T cells at
60% conﬂuence were transiently co-transfected using lipofect-
amine 2000 (Invitrogene), with either 4 lg of EGFP-ADAR2
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or EGFP-ADAR1 in the constant presence of 3 lg of GluR-B
minigeneB13 (miniB13), which was used as an exogenous
editable substrate. The miniB13 encodes a portion of the
editing-competent murine glutamate receptor GluR-B gene
that includes the Q/R and þ4 site that are edited mainly by
ADAR2 and the hot-spot 1 site mainly edited by
ADAR1.34,35 Forty-eight hours after transfection, total RNA
was extracted from the cells using TRIzol Reagent and the
transfection efﬁciency tested by real-time PCR experiments.
We then extracted the total RNA and performed RT-PCR
with speciﬁc oligonucleotides for both the endogenous
BLCAP mRNA with the oligonucleotides hBLCAP-50F and
hBLCAP-30RT and the exogenous miniB13 with speciﬁc
miniB13 oligonucleotides, mini13 FW 50-TTTAGCCTATGA-
GATCTG GATGTGC-30 and miniB13 Rev 50-GAA-
GATTCGTA GAATTTAAACG-30. The endogenous BLCAP
and the exogenous miniB13 were ampliﬁed, and the editing
level calculated by direct sequencing of the cDNA pools as
previously described32 (as for the miniB13) or the PCR prod-
ucts were subcloned into the T-easy vector (Promega) (as for
the BLCAP). After subcloning 30 individual cDNAs were
sequenced and A-G changes in the individual clones were
analyzed. For each sample, 2 independent RT-PCR reactions
were performed. Human astrocytoma cell lines A172 (ATCC
CRL-1620TM) and U118 (ATCC HTB-15TM) were grown in
DMEM supplemented with 10% FCS (Invitrogen) plus antibi-
otics. Astrocytoma cell lines were transfected with pEGFP
and EGFP-ADAR2 (8 lg) using lipofectamine 2000 (Invitro-
gene). After 48 h, the cells were collected and the endogenous
BLCAP cDNA analyzed for RNA editing.
RNA folding
Mfold web server was used for nucleic acid folding and
hybridization prediction.36,37
Results
Human BLCAP transcript is edited in its coding and
noncoding sequences
The human BLCAP gene is located on chromosome 20 and
comprises 2 exons separated by an intron (Fig. 1a). Exon 1
encodes a 50 sequence of the 50UTR. Exon 2 includes the
remaining sequence of the 50UTR, the coding region and the
30UTR. The coding sequence of the BLCAP gene is therefore
intronless (Fig. 1a). Editing has previously been reported to
occur in the human BLCAP transcript changing the second
amino acid of the protein at the Y/C editing site.38 We
Figure 1. New editing events in the human BLCAP transcript. (a) Schematic representation of the BLCAP pre-mRNA. Exon 1 encoding the
50UTR is represented in light blue with gray bars followed by the intron that divides the 50UTR in 2. Exon 2 encodes the remaining 50UTR
(light blue with gray bars), the coding sequence (red rectangle) and the 30UTR (light blue). Red dots indicate the editing sites in BLCAP
mRNA (50UTR and coding sequences). Red lines indicate the editing sites identiﬁed within the intron. (b) Sequences of BLCAP pre-mRNA.
Adenosines in red indicate the edited sites in the intron (small letters) and exon 2 (capital letters). The underlined sequence corresponds
to the coding region. The intron was found to be edited at 11 positions referred to as I1 to I11 from 50 to 30. The 50UTR was edited at 3
positions referred to as: 5a, 5b and 5c. In the coding sequence, the edited positions are named according to the amino acid change they
produce: Y/C, Q/R and K/R. Underneath, the sequences are shown the chromatograms of single clones after sequencing analysis of human
BLCAP pre-mRNA in normal bladder tissue. As these sequences are cDNAs, the inosines are read as guanosines and the uridines as
thymidines. The percentage of the editing events identiﬁed in the bladder tissue at different sites is shown in Table 3.
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wondered if other editing events were present in the human
BLCAP transcript that could increase the number of protein iso-
forms. For this purpose we ampliﬁed the BLCAP pre-mRNA
from human bladder with speciﬁc oligonucleotides as BLCAP is
particularly abundant in this tissue, and we performed sequence
analysis on pools as well as on single clones. We found that the
BLCAP pre-mRNA from the human bladder undergoes multiple
editing events in the coding, 50UTR and intronic sequences.
New editing events were found within exon 2 (Fig. 1a, red
dots) and within intron 1 (Fig. 1a, red lines). The human
BLCAP intron was edited in 11 speciﬁc sites that we term I1–
11 starting from the 50 to the 30 (Fig. 1b). The 50UTR, which
lies within exon 2, was also edited at 3 positions; 5a, 5b and 5c
(Fig. 1b). Most importantly, we found 3 editing events within
the coding region that changed the amino acid composition of
the protein. The tyrosine in position 2 of the protein was con-
verted into a cysteine (Y/C site) as previously reported.38 In
addition, we found 2 new editing events that converted the
glutamine at position 5 to arginine (Q/R site) and the lysine
at position 15 to arginine (K/R site) (Fig. 1b). Both the new
editing events, identiﬁed in the coding sequence, inserted a
positively charged amino acid within the BLCAP amino ter-
minus (Fig. 1b). The percentage of the editing events identi-
ﬁed in the bladder tissue at different sites is shown below.
Multiple alignments in different organisms of the BLCAP pro-
tein showed that this protein is highly conserved from
humans to Drosophila melanogaster and Caenorhabditis ele-
gans, particularly, at its amino-terminus, suggesting that it
may have a conserved biological role (Fig. 2). RNA editing
can alter this highly conserved portion of the protein by
changing 3 different amino acids that can produce up to 8
different protein isoforms (Fig. 2).
Both ADAR1 and ADAR2 enzymes can edit BLCAP
transcript in HEK 293T cells
As BLCAP transcript is edited at multiple sites, the question
therefore arose as to which ADAR editing enzyme was re-
sponsible for these editing events. We focused our attention
on the editing sites that are present in the BLCAP mRNA
as editing in the 50UTR and coding sequences could affect
both protein synthesis and function.2,39 To address this
question we transfected the HEK 293T cell line with either
EGFP-ADAR1, EGFP-ADAR2 or the empty vector. The
HEK 293T cell line is an ideal system for an editing assay
as this cell line displays a low level of an endogenous edit-
ing activity.18,33,40,41 To ensure comparable transfection efﬁ-
ciency, the percentage of EGFP-positive cells was deter-
mined by ﬂow-cytometric analysis (data not shown). We
analyzed ADAR1 and ADAR2 expression levels by real-time
PCR (Fig. 1S, panel A). To monitor the editing activity of
the transfected ADAR enzymes, we also cotransfected the
miniB13 that encodes a portion of the editing-competent
murine GluR-B gene that carry speciﬁc sites for both
ADAR1 and ADAR2 (Fig. 1S, panel B). BLCAP was ampli-
ﬁed with the oligonucleotides hBLCAP50F and hBLCAP30RT
as shown in Figure 3, and products subcloned into the T-
easy vector (Promega) and 30 individual cDNA clones
were sequenced and results are shown in Table 1.
We found that none of the 3 editing sites within the
50UTR (5a–c) were edited by ADAR1, whereas ADAR2 edited
the 5b site (23.3 %) as well as the 5c site (3.3%) (Table 1).
The Y/C site displayed a high level of editing (60%)
(Table 1) in the HEK 293T cell line overexpressing either
ADAR1 or ADAR2. Using the same cell assay, we found
that ADAR1 also edits the Q/R site to 24% but at a
very low level the K/R site, whereas the ADAR2 enzyme
was able to edit both the Q/R (50%) and K/R (40%)
sites to a comparable efﬁciency (Table 1). Low/undetect-
able editing level was found in HEK 293T transfected
with the pEGFP empty vector. Therefore, we can conclude
from this assay that both ADAR1 and ADAR2 can edit
all the sites present in the BLCAP mRNA coding
sequence, with ADAR2 showing a higher editing efﬁciency
at most sites.
Figure 2. Multiple alignments of BLCAP proteins. Multiple alignments of BC10 proteins. Initials correspond to hs, Homo sapiens; pt, Pan
troglodytes; bt, Bos taurus; mm, Mus musculus; rn, Rattus norvegicus; md, Monodelphis domestica; gg, Gallus gallus; xt, Xenopus
tropicalis; tn, Tetraodon nigroviridis; ga, Gasterosteus aculeatus; dr, Danio rerio; ag, Anopheles gambiae; dm, Drosophila melanogaster; ce,
Caenorhabditis elegans. Identical amino acid conservation among species is indicated in black. Residues identical in most of the species
analyzed are indicated in gray. Indicated in red are the amino acids found to be edited. Black lines above the alignment indicate the
hypothetical transmembrane domains (TM). Stars indicated the proline-rich motif at the N-terminus.
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hADAR2 edits the BLCAP mRNA in astrocytoma cell lines
To further analyze if ADAR2 was responsible for editing the
endogenous BLCAP transcript within the coding sequence we
used a different cell line. Astrocytoma cell lines have a very
low-endogenous ADAR2 editing activity as measured by edit-
ing of endogenous substrates such as GluR-B and GluR-6
transcripts.18 Therefore, we used the astrocytoma cell lines
(U118 and A172), both untransfected or transfected with the
pEGFP-ADAR2 construct or with pEGFP as a negative
control.
When we analyzed the editing of the endogenous BLCAP
transcript in astrocytoma cell lines, we observed a baseline
editing activity of 0–4.2% at the Y/C, Q/R and K/R sites in
all 4 control cell lines (U118, U118 EGFP, A172 and A172
EGFP) (Table 2).
As ADAR2 can edit all 3 sites within the coding region of
BLCAP in HEK 293T cells (Table 1), we expected an increase
in editing levels at these sites in astrocytoma cell lines trans-
fected with EGFP-ADAR2. We observed an increase in edit-
ing activity at the Y/C site (from 0–4.2% to 32–42%), Q/R
site (from 0–4.2% to 30–35%) and K/R site (from 0–4.2% to
8.5–15%) (Table 2). The 3 editing sites within the 50UTR
showed no editing. We found that 5% of the total BLCAP
transcripts were edited in the untransfected or control astro-
cytoma cell lines transfected with pEGFP. However, when
EGFP-ADAR2 was overexpressed, the level of the editing per
transcript increased by 6-fold in the U118 cell line and 10-
fold in the A172 cell line (Fig. 4). As ADAR2 can edit all 3
sites within the coding sequence of BLCAP, this enzyme
could strongly decrease the amount of the unedited BLCAP
isoform in a cell.
Co-ordination of intronic and exonic editing events of
BLCAP pre-mRNA
The editing sites in the human BLCAP transcript are clus-
tered in 2 speciﬁc regions in the pre-mRNA. The ﬁrst region
includes the last 150 nucleotides of the intron and the second
region includes the beginning of exon 2 (Fig. 1a). This obser-
vation raised the question if these 2 portions of the BLCAP
Figure 3. RNA editing in BLCAP mRNA. Schematic representation of
human BLCAP mRNA. Exon 1 is depicted in bold. The remainder is
exon 2 that encodes all the editing positions present in the mature
BLCAP RNA, 3 within the 50UTR and 3 within the coding sequence.
The amino acid sequence is below the nucleotide sequence. The
adenosines that are edited are bold and underlined. Arrows
identify the position of the oligonucleotides hBLCAP50F and
hBLCAP30RT used for the ampliﬁcation of BLCAP after RT-PCR.
Table 1. Editing of endogenous BLCAP mRNA, within EXON 2 in HEK 293T cells transfected with either ADAR2 or ADAR1
5a 5b 5c Y/C Q/R K/R n. clones
293T 0 0 0 5 0 0 28
293T ADAR1 0 0 0 58.6 24.1 10 30
293T ADAR2 0 23.3 3.3 56.6 50 40 30
Editing levels are expressed as percentages. In italics is the number of BLCAP clones that were sequenced.
Table 2. Modulation in BLCAP editing in astrocytoma cell lines
Glial tissues and cell lines
Editing in BLCAP exon 2
5a 5b 5c Y/C Q/R K/R n. clones
U118 astrocytoma cell line 0 0 0 4.2 4.2 4.2 24
U118 transfected with pEGFP 0 0 0 0 0 4 18
U118 transfected with pEGFP-ADAR2 0 0 0 32 29.8 8.5 47
A172 astrocytoma cell line 0 0 0 3.1 3.1 3.1 32
A172 transfected with pEGFP 0 0 0 0 0 0 27
A172 transfected with pEGFP-ADAR2 0 0 0 42 35 15 28
Editing levels are expressed as percentages. In italics is the number of BLCAP clones that were sequenced.
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pre-mRNA could form a duplex that would be recognized by
ADARs. It has been well established that many A-to-I edit-
ing sites occur in clusters that are conserved. The editing
complementary sequences (ECSs) form an imperfect duplex
with the edited region35 and are often found within an
intron. As intronic ECS is often conserved among species,
we performed multiple alignments of mammalian BLCAP
pre-mRNA and indeed we found a high level of conserva-
tion in the last 150 nucleotides of the intron and the begin-
ning of exon 2 (Fig. 5).
Then, we analyzed the human BLCAP pre-mRNA by
RNA folding algorithm. A stable secondary structure was
predicted to be formed between the intron and the coding
region, highlighted in yellow in Figure 5, which includes all
the editing sites found in this study.
In Figure 6a a portion of the predicted dsRNA structure,
which includes the editing sites I4–I9, 5b, 5c, Y/C and Q/R,
is shown. It is likely that this duplex is required for the edit-
ing events found within the intron and the exon of BLCAP.
If this prediction was true, then the exonic and intronic edit-
ing events would be linked and occur simultaneously. We
therefore analyzed the editing events in both the exonic and
intronic regions of BLCAP in normal brain, brain tumor
(astrocytoma grade IV) and astrocytoma cell lines untrans-
fected and transfected with the editing enzyme ADAR2 as
ADAR2 edited most of the exonic sites studied at a higher
level (Tables 1 and 2).
Tissues and cell lines used in this study are identiﬁed by
progressive identiﬁcation numbers ID (see Material and
methods section). Normal white matter (ID 6) displayed a
high level of editing of transcripts edited in both the exon
(20%) and the intron (40%) (Fig. 6b). However, the corre-
sponding astrocytoma tumor (ID 18) and astrocytoma cell
lines U118 and A172 (from now on referred to as ID 19 and
20, respectively) showed a decrease in editing of both exonic
and intronic sites with 0–5% of transcripts being edited
within the exon and 2–10% being edited within the intron
(Fig. 6b). When we increased the editing activity in these
cells by over-expressing ADAR2, we observed an increase in
Figure 5. Alignment of BLCAP pre-mRNA in mammals. Alignment of BLCAP pre-mRNA among mammals identiﬁed by initials that correspond
to hs, Homo sapiens; pt, Pan troglodytes; bt, Bos taurus; mm, Mus musculus; rn, Rattus norvegicus. (a) Upper alignment corresponds to
the last 200 nucleotides of the BLCAP intron. (b) The lower alignment corresponds to the start of exon 2 in BLCAP. Nucleotide positions
found edited in human are highlighted in green. The ﬁrst ATG of the coding sequence corresponds to nucleotides 734–736 in (b).
Sequences predicted to base pair to form an RNA duplex are highlighted in yellow. Identical nucleotides are indicated in black.
Figure 4. Increased editing activity observed on BLCAP mRNA.
A172 and U118 astrocytoma cell lines were transfected with EGFP
empty vector or a vector expressing EGFP-ADAR2. The editing
events present in BLCAP mRNA are expressed as a percentage (y-
axis). On the x-axis are the untransfected astrocytoma U118 and
A172 cell lines, the cell lines transfected with EGFP vector and
with EGFP-ADAR2. ADAR2 increased the number of BLCAP
transcripts undergoing editing in both cell lines.
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editing in the exon but also in the intron (ID19-ADAR2 and
ID20-ADAR2 in Fig. 6b).
The relationship between the editing events in exon 2 and
the intron of the BLCAP transcript in these samples was eval-
uated with regression analysis. RNA editing in the intron dis-
played a high correlation with the editing in the exon 2 (R2
¼ 0.85) (Fig. 6c), suggesting that the editing events in the
intron and exon 2 occurred in concert.
Human BLCAP transcript displays diverse editing levels in
nervous and non-nervous tissues
As BLCAP is expressed in different human tissues, we wanted
to determine if the new editing sites found in bladder tissue
were present in other tissues and to what extent they were
edited. We focused on the editing sites that are present
within the mRNA of BLCAP. We analyzed the 3 editing
events in the 50UTR (5a, 5b and 5c) and the 3 editing events
in the coding sequence (Y/C, Q/R and K/R) in various
human tissues and cell lines that are identiﬁed by progressive
identiﬁcation numbers (ID). BLCAP mRNA was found to be
edited in a wide range of human tissues, such as heart, blad-
der, lymphocytes, ﬁbroblast, epithelial cells and brain (Table
3). However, equivalent editing positions in different tissues
were found to be edited to differing extents with the heart
and ﬁbroblast mRNAs being edited to a low level at all 6
editing sites and bladder with the highest level of editing (Ta-
ble 3). Heart and ﬁbroblast displayed the lowest level of RNA
editing with 5.1% at the Y/C site, 3.8% at the Q/R site and
1.3% at the K/R site in heart (ID 1) and 7.7% editing at the
Y/C and Q/R sites and 0% at the K/R site in ﬁbroblasts (ID
5) (Table 3). Bladder tissue (ID 2) had the highest editing ac-
tivity with 27.6% at the Y/C site, 15.8% at the Q/R site and
5.3% at the K/R site, respectively (Table 3).
It has been shown previously that ADAR1 plays a major
role in editing the Y/C site in mouse brain.42 In this study,
we observed that the Y/C site is edited in human cell lines by
both ADAR1 and ADAR2. Moreover we found that the K/R
site seems to be preferentially edited by ADAR2 in an over-
expressing cell system in HEK 293T and astrocytoma cell
lines.
Figure 6. Comparison of editing within the intron and exon of
BLCAP. (a) A portion of the predicted dsRNA structure formed
between the intron and exon 2 is shown. The hypothetical ECS
is also indicated. (b) The editing events present in BLCAP
mRNA are expressed as a percentage (y-axis) and tissues, and
cell lines are indicated with their ID identiﬁcation number in all
the samples studied (x-axis). The number of transcripts edited
in the intron (in white bars) and in the exon (black bars) are
shown. (c) Correlation of RNA editing between exon 2 and the
intron in BLCAP. RNA editing within the BLCAP intron is
expressed as a percentage (y-axis) and plotted against RNA
editing within the BLCAP exon 2 (x-axis). Analysis was
performed with linear regression; P values and R2 coefﬁcients
are shown.
Table 3. Editing of BLCAP mRNA, within EXON 2 in various human tissues
Tissues ID Tissues
Editing in BLCAP exon 2
5a 5b 5c Y/C Q/R K/R n. clones
1 Heart 1.3 0 1.3 5.1 3.8 1.3 78
2 Bladder 5.3 2.6 1.3 27.6 15.8 5.3 76
3 Normal lymphocytes, patient 2,630 17 3 3 15.5 11.3 2.8 71
4 Normal epithelial mucosa, patient 2,630 nm 15 3.7 0 9.3 9.3 0 54
5 Skin ﬁbroblasts cell lines, patient 2,630 0 0 0 7.7 7.7 0 13
6 White matter (temporal lobe) patient 22 0 0 3.2 16.1 19.4 19.4 31
Editing levels are expressed as percentages. In italics is the number of BLCAP clones that were sequenced.
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Therefore, we can conclude that ADAR2 appears to be
more active in editing this transcript in the brain (K/R site ¼
19.4%) than in other tissues (Table 3); however, ADAR1
alone or in concert with ADAR2 seems to be more active in
editing this transcript in bladder (Y/C site ¼ 27.6%), lym-
phocytes (Y/C site ¼ 15.5%) and brain (Y/C site ¼ 16.1%)
compared with other tissues (Table 3). Real-time experi-
ments on human normal tissues extracted from heart, brain,
lymphocytes and bladder (see Table 3) were performed to
analyze the ADAR mRNA expression levels. Indeed, we
observed that tissues with a high-editing level such as lym-
phocytes and bladder tissues (Table 3) also displayed a
high-expression level of ADAR1 and/or ADAR2 (Fig. 2S).
The brain tissue with a high level of edited BLCAP tran-
script showed a low level of ADAR1 mRNA, but this is
compensated by a high level of ADAR2 mRNA expression
(Fig. 2S). Finally heart tissue with the lowest percentage of
BLCAP editing level among the tissues tested (Table 3) also
showed the lowest level of mRNA expression of both
ADAR1 and ADAR2 (Fig. 2S).
A general decrease in editing activity of the human BLCAP
transcript in cancerous tissues
As A-to-I editing was found to be downregulated in various
tumor tissues compared with the normal control tissues17,18,20
and considering that we observed a decrease in editing level
in astrocytoma grade IV and astrocytoma cell lines compared
with normal white matter (Fig. 6b), we wondered if this
would also be observed in tumors from other tissues. We an-
alyzed the editing frequencies at the new editing sites in the
BLCAP transcript in normal and cancerous tissues and cells
lines (Table 4). Despite the small number of patients ana-
lyzed in this study, we found a general decrease in editing in
the BLCAP mRNA in cancerous cell lines (Table 4, samples
in dark gray) and cancerous tissues (Table 4, samples in light
gray) when compared with normal tissues (Table 4, samples
in white). In particular, tissues with a higher level of editing
activity such as bladder and brain had a greater decrease in
editing at speciﬁc sites. In normal bladder tissue (ID 2), edit-
ing at the Q/R site was 15.8%, whereas in transitional cell
carcinoma (TCC) and bladder cancer cell lines editing at this
site ranged from 3.6 to 8.2% (ID 7–9). Analysis of the K/R
site revealed editing levels of 5.3% in normal bladder but in
bladder cell lines editing at this site ranged from 0 to 1.5%
(ID 10–12) and from 3.4 to 8.2% in invasive TCC (ID 7–9)
(Table 4).
In normal tissue, editing activity in the white matter (ID
6) was 19.4% at the Q/R site, and this was reduced to 0–4%
in cancer tissue and cell lines (ID 18–20). Similarly, the K/R
site in white matter was edited to 19.4%, and it decreased to
0–4.2% in tumors and cancer cell lines (ID 18–20).
The editing sites within the 50UTR were found to be
edited to a very low level even in normal tissues (Table 4,
samples in white), whereas, in most cancers and cell lines,
Table 4. Editing level of BLCAP mRNA within EXON 2 in cancerous tissues and cell lines and noncancerous tissues
Tissues ID Tissues and cell lines
Editing in BLCAP exon 2
5a 5b 5c Y/C Q/R K/R n. clones
2 Bladder WT 5.3 2.6 1.3 27.6 15.8 5.3 76
7 Non invasive TCCs, bladder cancer grade II 0 0 1.1 16 7.8 3.4 88
8 Invasive TCCs, bladder cancer grade III 5.5 1.8 0 9.2 7.4 3.7 54
9 Invasive TCCs, bladder cancer grade III 727-1 6.5 6.5 8.2 19.7 8.2 8.2 61
10 HU 609, bladder cell line (TCC) 0 0 0 7.1 3.6 0 28
11 HCV 29, bladder cell line (TCC) 0 2.4 0 7.1 4.8 0 42
12 T24, bladder cell line (TCC) 0 0 0 10.8 4.6 1.5 65
4 normal epithelial mucosa, patient 2630nm 15 3.7 0 9.3 9.3 0 54
13 cancerous epithelial cells from patient 2630 0 2.4 7.1 2.4 0 12 42
14 cancerous epithelial cells from patient 425 2.5 0 2.5 5 5 2.5 40
15 VACO425, epithelial cell line derived from patient 425 0 0 0 15 7.4 3.7 54
16 CACO2 epithelial colorectal cancer cell line 0 0 0 0 0 0 22
17 HRT18 epithelial colorectal cancer cell line 0 0 0 0 0 0 16
6 White matter, (temporal lobe) patient 22 0 0 3.2 16.1 19.4 19.4 31
18 GBM (astrocytoma grade IV), temporal lobe, patient 22 0 0 0 0 0 0 17
19 Cell line U118 derived from glioma 0 0 0 4.2 4.2 4.2 24
20 Cell line A172 derived from glioma 0 0 0 3.1 3.1 3.1 32
21 HeLa cell line 2.4 0 0 23.8 16.7 2.4 42
Indicated in white are control human tissues, in gray tumor tissues and in dark gray cancerous cell lines. Editing levels are expressed as
percentages. In italics is the number of sequenced BLCAP clones.
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these editing sites are basically not edited (Table 4, samples
in light and dark gray).
Nevertheless, there were some exceptions such as the epi-
thelial colorectal cancer cell line (ID 15) from patient 425
that had 15% editing at the Y/C site, which is higher than
the normal control (ID 4) (Table 4).
Furthermore, we analyzed if a correlation exists between
grade of malignancy of the tumors and percentage of editing
at Y/C, Q/R and K/R sites in 7 pediatric astrocytomas at
increasing grade of malignancy from astrocytoma grade I to
astrocytoma grade IV also known as glioblastoma multiforme
all dissected from the Temporal/Frontal lobe. Despite our
small cohort of patients, we found a good correlation
between a decrease in editing level at the Q/R and K/R edit-
ing sites of BLCAP and the increase of the histological malig-
nancy of the tumors (Fig. 3S), however, poor correlation was
observed for the Y/C editing site (Fig. 3S).
Discussion
BLCAP is a highly conserved protein present in all species
from C. elegans to humans. Despite its high protein conserva-
tion (Fig. 2), the function of this protein is still unknown.
Multiple alignments of BLCAP pre-mRNA from different
species show that conservation extends into the RNA level
including noncoding regions such as the 50UTR and the
unique intron (Fig. 5). As UTRs and introns in eukaryotes
are generally under less selective pressure than the coding
regions,43 the conservation of these regions in BLCAP pre-
mRNA may reﬂect the presence of speciﬁc consensus sequen-
ces that are important for posttranscriptional regulation of
the transcript such as RNA editing. In fact, a duplex RNA
structure comprising of the conserved intronic region and
the exon 2 was predicted (Fig. 6a). Double-stranded RNAs
are indeed substrates for ADAR enzymes and, as expected,
the human BLCAP pre-mRNA undergoes multiple editing
events in the predicted dsRNA structure.
A total of 17 editing sites were found in the human
BLCAP pre-mRNA (Fig. 1). Eleven editing sites were identi-
ﬁed within the intron (I 1–11), 3 within the 50UTR (5a–c)
and 3 in the coding sequence (Y/C, Q/R and K/R) (Fig. 1).
The 3 editing events within the coding region of BLCAP can
change the amino acid composition of the protein, thereby
generating up to 8 different BLCAP protein isoforms. As the
coding region of this gene is intronless (the only intron lies
within the 50UTR), RNA editing is an important way to gen-
erate protein isoforms. Importantly, the 3 editing events
occurred within the coding region of the BLCAP mRNA
lying within the most highly conserved region of the protein
within the N-terminus before the hypothetical ﬁrst TM1.
These editing events (Q/R and K/R) introduced a positively
charged amino acid. The new Q/R editing event, found in
this study, generates an important amino acid change as it
substitutes an uncharged residue (Q) with a positively
charged and bigger residue (R). Interestingly, the other new
K/R editing site, that also introduced an arginine, lies within
the hypothetical proline-rich domain at the N-terminus of
the protein (Fig. 2). The proline-rich domain is commonly
found in proteins involved in cytoskeleton rearrangement,
signaling cascades and initiation of transcription.44,45 As the
biological role of this protein is still unknown, we can only
speculate on the possible consequence of the editing events.
As BLCAP is edited at multiple sites within its coding
regions and it is abundantly expressed in brain, it was likely
that ADAR2 could play a major role in editing this tran-
script. However, it seems that both ADAR enzymes edit in
vivo the Y/C site previously identiﬁed42 with a major contri-
bution due to ADAR1.42,46 We conﬁrmed, using a different
system, that both ADAR1 and ADAR2 can edit the Y/C site
(Table 1). We analyzed editing of the endogenous BLCAP
transcript in a cell line in which we overexpressed either
ADAR2 or ADAR1. In this assay, we found that in HEK
293T both editing enzymes can edit BLCAP transcripts to a
varying extent (Table 1). Interestingly, the K/R site appears
to be preferentially edited by ADAR2 (Table 1).
As BLCAP is expressed in different human tissues, we
investigated differences in editing occuring in different tissues.
Interestingly, equivalent editing positions in different tissues
were found to be edited to differing levels with the heart and
ﬁbroblast mRNAs being edited at a very low level, however,
bladder, brain and lymphocytes showed a higher editing activ-
ity (Table 3), and the consequence of this would be that differ-
ent ratios of BLCAP protein isoforms is present in different
tissues.
As BLCAP transcript is ubiquitously expressed and edited
to varying extents in different tissues, it could be useful as a
comparative editable transcript for further studies on the ﬁne
tuning and regulation of ADARs editing activity in vivo.
Furthermore, we also tested the editing level of BLCAP in
a cohort of patients, and we found a general decrease in edit-
ing activity in tumors versus tissues of non-tumoral origin. In
particular we analyzed astrocytomas, bladder carcinoma and
colorectal carcinoma (Table 4).
This observation is of interest as there is growing evidence
showing an overall downregulation of A-to-I RNA editing in
tumor tissues when compared with control tissues not only in
brain18,20 but in different tumor tissues such as placenta, testis,
kidney, lung, prostate and muscle.17 The reason why ADARs
have different activities in tumor tissues versus controls is not
yet fully understood. Nevertheless, it has been reported that
altered ADARs mRNA levels is present in brain tumors com-
pared to normal tissues.17,18 However, it is unlikely that the
expression level of ADARs proteins is the only parameter that
can explain the modulation in editing in normal versus patho-
logical conditions. Indeed, it has been recently shown that
ADARs activity can be inﬂuenced by the presence of a regula-
tory network of proteins and/or RNAs that could modulate
their function.5,18,47–50 BLCAP was ﬁrst identiﬁed in a screen
for genes contributing to the invasive phenotype of renal, cer-
vical and bladder cancer (TCC) as its transcript was found to
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be downregulated in these tumors.28,30,31 Furthermore, herein,
we found that BLCAP edited isoforms are reduced in different
type of cancers. In addition, despite our small cohort of
tumors samples, we observed that a correlation exists between
a decrease in ADAR-mediated RNA editing on BLCAP tran-
script and the histological grade of malignancy in pediatric
astrocytomas (Fig. 3S).
Therefore, in cancers, BLCAP transcript is not only down-
regulated but is also less edited. This study opens up an addi-
tional question to be addressed by future work as to whether
the editing events identiﬁed herein can contribute to the
appearance or progression of different human cancer.
A recent work reported no signiﬁcant changes in editing
levels between normal tissues and urinary bladder neo-
plasm.51 Differences existing between this observation and
this study could be due to different patients enrolled and/or
different methods used to identify editing events.
In conclusion, we identiﬁed new editing sites within the
human BLCAP transcript that required both ADAR1 and
ADAR2. The editing sites in different human tissues are dif-
ferently edited. Furthermore, the ﬁnding that BLCAP editing
is downregulated in various cancerous tissues could be valua-
ble for future improved diagnosis and therapies.
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